Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 428 across all filing types
Latest filing 2024-09-28 Regulatory Filings
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Regulatory Filings
2024-09-28 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to the National Stock Exchange of India Limited regarding the closure of the trading window for insiders due to the upcoming release of the company's un-audited financial results for the second quarter and half year ended 30th September 2024. It does not contain any financial data or detailed report but is an announcement related to trading restrictions ahead of financial results publication. The document length is only 1625 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2024-09-28 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed communication addressed to the National Stock Exchange of India regarding the proceedings of the 17th Annual General Meeting (AGM) of Vaishali Pharma Limited held on 27th September 2024. It includes information about the meeting's commencement and conclusion times, the quorum, the agenda items transacted (including adoption of audited financial statements, director appointment, share split, increase in authorized share capital, and issuance of bonus shares), and details about voting and shareholder attendance via video conferencing. The document does not contain the full financial statements or detailed financial performance data but rather summarizes the meeting proceedings and resolutions passed. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or the proceedings thereof. The document length is under 5,000 characters and is a report of the meeting proceedings, not the full annual report or voting results. Therefore, the correct classification is AGM Information (AGM-R).
2024-09-27 English
Board Meeting — VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 03-Oct-2024 to consider Other business.
Regulatory Filings
2024-09-24 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release dated September 24, 2024, announcing Vaishali Pharma's strategic plans for mergers and acquisitions to expand its product portfolio and strengthen its market position. It references an upcoming board meeting to discuss these plans further. The document is addressed to the National Stock Exchange of India and is issued pursuant to a regulatory requirement (Regulation 30 of SEBI LODR). The content focuses on announcing strategic corporate actions rather than providing detailed financial data, merger transaction documents, or tender offer filings. It is not a full merger filing (MA or TAR), nor is it a financial report or earnings release. The document is a corporate announcement about planned M&A activity, which fits best under the category of M&A Activity (TAR) as it relates to announcements and documents about merger proposals or takeover bids. The document length (6093 characters) and content confirm it is a substantive announcement rather than a brief notification or report publication announcement.
2024-09-24 English
Board Meeting — Other business matters
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled for October 3, 2024, sent to the stock exchange. It includes agenda items such as appointment of an additional director, revision of remuneration for directors, alteration of the Memorandum of Association, and discussion on expansion and acquisition strategy. The document is an announcement of an upcoming board meeting and changes in board composition and management remuneration, not the actual report or minutes of the meeting. It is not a full management report or financial report but an official communication about board/management changes and related agenda. Therefore, it fits best under 'Board/Management Information' (MANG). The document length is short and it is clearly an announcement, not a report or transcript.
2024-09-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.